Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

699
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
699
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.5K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
Dementia01:30

Dementia

458
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
458
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

873
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
873

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Zika virus infection induces a persistent accumulation of Alzheimer's disease-like Tau phosphorylation in adult immunocompetent mice in association with memory and social behavior impairments.

Acta neuropathologica communications·2026
Same author

Emerging directions in tauopathy research.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Tau profiling of brain extracellular vesicles reveals PHF6 peptide as core for pathological tau seeding in Alzheimer's disease.

Journal of biomedical science·2026
Same author

AETA peptide contributes to Alzheimer's disease signature of synapse dysfunction.

Acta neuropathologica·2026
Same author

Tanycytic degeneration impairs tau clearance and contributes to Alzheimer's disease pathology.

Cell press blue·2026
Same author

A Proline-Rich-Domain-Binding Single Domain Antibody Selectively Inhibits RNA-Induced Phase Separation of Tau.

ACS chemical neuroscience·2026

Related Experiment Video

Updated: Dec 27, 2025

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia
07:18

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

8.8K

Dementia Therapy Targeting Tau.

Luc Buee1

  • 1University of Lille, INSERM, CHU-Lille, Alzheimer & Tauopathies, LabEx DISTALZ, Lille, France. luc.buee@inserm.fr.

Advances in Experimental Medicine and Biology
|February 26, 2020
PubMed
Summary
This summary is machine-generated.

Researchers are exploring therapeutic strategies for tauopathies, like Alzheimer's disease, focusing on the tau protein and its gene, MAPT. However, a deeper understanding of tau's normal functions is crucial for developing effective treatments.

More Related Videos

A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid
06:22

A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid

Published on: September 3, 2021

3.9K
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
09:22

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

18.8K

Related Experiment Videos

Last Updated: Dec 27, 2025

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia
07:18

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

8.8K
A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid
06:22

A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid

Published on: September 3, 2021

3.9K
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
09:22

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

18.8K

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Genetics

Background:

  • Tau protein is primarily known as a microtubule-associated protein.
  • Tau aggregates are hallmarks of Alzheimer's disease and other neurodegenerative tauopathies.
  • The aggregation of tau can be influenced by genetic mutations (MAPT gene), alternative splicing, post-translational modifications, and truncation.

Purpose of the Study:

  • To review current research on the therapeutic potential of targeting the tau protein and its gene, MAPT.
  • To highlight the challenges in developing tau-targeting therapies due to incomplete knowledge of tau's physiological roles.

Main Methods:

  • Literature review of ongoing therapeutic strategies for tauopathies.
  • Analysis of factors contributing to tau aggregation.

Main Results:

  • Various therapeutic strategies targeting tau and MAPT are under investigation.
  • A significant knowledge gap exists regarding the normal physiological functions of tau protein.
  • This lack of understanding impedes the progress of therapeutic interventions.

Conclusions:

  • Developing effective treatments for tauopathies requires a comprehensive understanding of tau's normal functions.
  • Further research into tau's physiological roles is essential to overcome therapeutic hurdles.